Loading clinical trials...
Loading clinical trials...
A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and AD Patients
Conditions
Interventions
BBT001
Placebo
Locations
7
United States
Equity Medical, LLC
The Bronx, New York, United States
Linear Clinical Research
Perth, Western Australia, Australia
Optimal Clinical Trials Central Auckland
Grafton, Auckland, New Zealand
Aotearoa Clinical Trials
Otahuhu, Auckland, New Zealand
Pacific Clinical Research Network (PCRN) - Auckland
Takapuna, Auckland, New Zealand
Optimal Clinical Trials Ltd - Christchurch
Christchurch Central City, Christchurch, New Zealand
Start Date
February 27, 2025
Primary Completion Date
August 21, 2026
Completion Date
February 6, 2027
Last Updated
November 17, 2025
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
NCT07265479
Lead Sponsor
Bambusa Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions